BIG against breast cancer

✍️ We are pleased to announce the official signing of the European Project « Path4Young »! 🔬 On October 19th, BIG, with Unicancer, University of Warwick, Gustave Roussy, and 22 additional partners, signed a Grant Agreement for an ambitious new European project called Path4Young, led by Dr Ines Vaz-Luis from Gustave Roussy. The goal is to improve care for young women with hormone receptor-positive breast cancer (HR+). This European Union-funded project, based on an ongoing international multicenter clinical trial OPTIMA (@OPTIMAbstudy), seeks to redefine the care standards for premenopausal women considered at high risk of recurrence. 💡 This project represents a major step forward in tailoring breast cancer treatment for young women and providing innovative solutions to better support patients. Learn more about #Path4Young and our mission to reshape breast cancer care on our website: https://lnkd.in/eYpT_ADr 🌐 Unicancer, Gustave Roussy, Università degli Studi di Torino, Institut Jules Bordet, EUPATI, University of Warwick, Resilience, HeCOG, Cancer Trials Ireland Austrian Breast & Colorectal Cancer Study Group (ABCSG), GEICAM - Spanish Breast Cancer Group, GAICO, GECOPERU, LACOG - Latin American Cooperative Oncology Group, GOIRC, Europa Donna Slovenija, Instituto D'Or de Pesquisa e Ensino, AP-HP, Assistance Publique - Hôpitaux de Paris, IH, SOLTI, CEEOG, Dana-Farber Cancer Institute, Universidad de Castilla-La Mancha, Clinical Research Technology, Klineo #BreastCancer #Research #BIGagainstBC #HorizonEU European Commission European Health and Digital Executive Agency (HaDEA) #HaDEA

We'd like to express our heartfelt thanks to the European Commission and the European Health and Digital Executive Agency (HaDEA) for the invaluable support that #EU4Health co-funding is providing us this year. From our Pink October campaign to a special event with Her Majesty the Queen of the Belgians, and a gala evening to celebrate BIG's 25th anniversary, each of these meaningful activities was greatly enhanced by EU co-funding and the support we received from the European Commission and HaDEA. For the second consecutive year, the Breast International Group (BIG) has been awarded an operating grant under the EU4Health programme. This funding is crucial to support the activities of our organisation, which facilitate academic research for breast cancer. #BIG25years #BIGagainstbc #breastcancer #research

Our work describing HER2-positive breast cancer heterogeneity (from my PhD with Christos Sotiriou at Institut Jules Bordet) is out in Nature communications. ➡️We identified 5 molecular subtypes 🧬 in the ALTTO clinical trial (BIG against breast cancer) with external validations. ➡️We captured both tumor-intrinsic and microenvironment features. ➡️The subtypes showed prognostic value and, in neoadjuvant cohorts, differences in pCR rates. Grateful to Christos Sotiriou for his guidance, the team at the BCTL, and all co-Authors.

We are thrilled to announce that clinical and molecular data from the #LORELEI study are now accessible on the Vivli platform! 🔗 https://shorturl.at/YQMw4 The LORELEI study is a pivotal phase II, international, randomized, double-blind trial focused on ER-positive/HER2-negative early-stage breast cancer in postmenopausal women. By comparing letrozole plus taselisib (GDC-0032) with letrozole plus placebo, the study sought to uncover critical insights into treatment resistance and sensitivity in breast cancer therapy. Researchers can now delve into this rich dataset to advance understanding and spark new innovations in breast cancer care. 👏 A huge thank you to the LORELEI study team for enabling this milestone and empowering the research community with these insights. Austrian Breast & Colorectal Cancer Study Group (ABCSG), SOLTI #cancerresearch #Breastcancer #Research #BIG25years #EU4Health European Health and Digital Executive Agency (HaDEA)

Servaas Michielssens, PhD, CFA, our Head of Healthcare at Candriam, had the honour of participating in a meaningful roundtable discussion organized by BIG against breast cancer, attended by Her Majesty Queen Mathilde of Belgium. The event, which took place at TheMerode in Brussels, was a unique gathering of scientists, patient advocates, business leaders, and dedicated supporters, highlighting the latest advancements in breast cancer research and the impact of BIG's 25 years of dedication. Servaas engaged in insightful conversations about the urgent need for continued support of breast cancer research, emphasizing the importance of partnerships that can drive progress and improve the lives of patients worldwide. Our heartfelt thanks to Her Majesty Queen Mathilde for her commitment to this vital cause and to BIG for creating a space for such impactful discussions. Together, we can continue to make strides in the fight against breast cancer. 💖🎗️ #Investing4Tomorrow #BIGagainstbc #Healthcare #CancerResearch #SustainableInvesting #EU4Health

Thanks Philippe together with the coPIs Matteo Benelli and Angel Guerrero-Zotano , and all BIG against breast cancer colleagues for this huge, inspiring effort! Proud to be onboard 😊😊😊

We're pleased to share that the latest issue of the BIG Research in Focus is now available! This special edition commemorates 25 years of research and advancements in the fight against breast cancer. 👉🔗 https://shorturl.at/wALNj Explore a quarter-century of scientific progress and the significant impact of collaborative efforts in this essential publication. 📖 #BIGagainstBC #breastcancer #Research #BIG25Years #EU4Health European Health and Digital Executive Agency (HaDEA)

🙌 We extend our heartfelt gratitude to Infoblox for their generous support through their Step Challenge in support of BIG. 🎀 On 29 October, Infoblox encouraged their APJ employees to achieve an average of 5.000 steps each that day, pledging a $5.000 donation to BIG if the goal was met. 🚶♂️💪 An impressive 259 Infoblox employees took up the challenge, collectively walking an astounding 4.239.400 steps! Their enthusiastic participation not only surpassed the target but also resulted in a meaningful donation to BIG's breast cancer research. A BIG thank you. 🙏 #BreastCancer #Research #BIG25Years #EU4Health European Health and Digital Executive Agency (HaDEA)

We extend our congratulations to Siobhan Gaynor, a patient advocate, and her co-authors for the publication of their patient-led survey on the information and communication needs of individuals with metastatic breast cancer (MBC) in Ireland and Northern Ireland. We are delighted to see all of Siobhan's work recognised and disseminated with her as the first author of this paper. 👏 The results of this survey show that 77% of respondents wanted more prognostic information. In addition, patients also need better access to their medical records and support with symptoms, including mental health issues. Their work is a significant step forward in improving patient care, providing valuable insights that will shape the future of MBC treatment and breast cancer research. 👉 🔗 https://shorturl.at/Fkxo7 We take this opportunity to thank Siobhan for her participation in the 𝗕𝗜𝗚 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲 over the past 3 years. We are so grateful for your valuable input and your support of BIG research. 🙏💚 Cancer Trials Ireland #BreastCancer #Research #EU4Health European Health and Digital Executive Agency (HaDEA)

At the recent ESMO - European Society for Medical Oncology Congress, Prof. Gabriele Zoppoli presented the latest findings from the AURORA research programme. These insights reveal significant age-related molecular differences in advanced #breastcancer. 💡 Curious to learn more? Some articles were recently published by: 🔗 MediMix: https://shorturl.at/Azuxj 🔗 Video Journal of Oncology (VJOncology): https://shorturl.at/Ah8qV 🔗 OncologyEducation: https://shorturl.at/xwlMx Thanks to #AURORA, we’re gaining a clearer understanding of metastatic breast cancer! The Breast Cancer Research Foundation Philippe Aftimos MD European Health and Digital Executive Agency (HaDEA) #EU4Health